1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

Fixing Part D Coverage Gap ‘Cliff’ Is Right Way To Lower Costs, PhRMA Says

 
• By Cathy Kelly

PhRMA pushing for legislation to address upcoming surge in Medicare Part D out-of-pocket spending requirements and reverse the recently-enacted increase in the discount on branded drugs in the coverage gap.

PS1801_Prescription Pad_593365520_1200.jpg

A little- known provision in the Affordable Care Act that suppressed the upward trend in out-of-pocket spending required before Medicare Part D beneficiaries emerge from the coverage gap and reach catastrophic coverage is slated to sunset in 2019.

That could mean that unless Congress changes things, seniors will face nearly $1,500 in additional costs in 2020 before they reach the catastrophic phase of the benefit and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Proposed HHS Budget Would Eliminate Medicare Negotiation Program Start-Up Funding

 
• By Cathy Kelly

The preliminary budget document supports legislation clawing back funds appropriated for the program.

Medicare Price Negotiation: Trump Order Adds Momentum To ‘Pill Penalty’ Fix

 
• By Cathy Kelly

Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.

More from Government Payers